Awaiting product image

Article: RELEVANCE: A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat

€2.42

SKU: product-article-21094 Category:

Description

RELEVANCE: A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat

Reviews

There are no reviews yet.

Be the first to review “Article: RELEVANCE: A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat”

Your email address will not be published. Required fields are marked *

Related products